Please find all related articles below.
The number of reports of medicine shortages in the EU is increasing. Shortages are occurring across the supply chain and all classes of medicines are affected, from complex chemotherapy agents and anaesthetics to diabetes, hypertension, and asthma medication.
This article is a contribution by the Pharmaceutical Group of the European Union (PGEU)
There are a number of reasons why some medicines are sometimes unavailable. The medicines supply chain is highly complex and its efficiency (...)
EPHA has produced a briefing on financial conflicts of interest and research in health in light of growing evidence from the tobacco, pharmaceutical and medical fields that the funding source for research may compromise results in favour of commercial interests . In this briefing, EPHA explores if there is a risk that these biases could be extended to nutrition and alcohol science. The purpose of the briefing is to explore academic literature, tools to protect research from conflicts of (...)
EPHA hosted a seminar on Monday 19 November 2012 to clarify certain elements of the proposal for a revision of the rules on data protection.
The European Commission released its revision of the 1995 Data Protection legislation in January of this year, proposing a number of measures which directly affect public health.
In order to examine the exact implications for areas such as healthcare, patient protection and medical research, EPHA hosted a seminar clarifying the health matters (...)
The extraordinary November Summit will focus solely on the EU Budget. Heads of State will defend the budget lines that their countries receive funds from. In this context, members of the Civil Society Contact Group call for a re-prioritisation of EU funds to where they have the biggest impact on the environment, extreme poverty, and people living in Europe.
The 22-23 November European Council is a crucial summit for ensuring that the next MFF delivers adequate financing for sustainable (...)
EPHA’s position on the General Data Protection Regulation highlights the strengths and weaknesses of the existing proposal from the perspective of the health community and lays out the key provisions in protecting patient safety, individual rights and public health.
The European Commission (EC) is currently reviewing its existing legal framework on data protection to ensure that the rules are fit for dealing with increasingly complex and sophisticated developments in technology and (...)
On 25 October, the European Commission unveiled its 2013 work programme. Its overarching goal is to put the EU back on the road to sustainable growth. This will entail economic reforms, skills development, research and innovation, and changes in the single market.
In the field of health, there are several initiatives mentioned for next year:
Review of the Thematic Strategy on air pollution and associated legislation - assess the implementation and achievements of current air pollution (...)
The 15th European Health Forum Gastein (EHFG) took place between 3-6 October 2012 in Austria. This year’s conference theme was “Crisis and Opportunity – Health in an Age of Austerity’’, and the various plenary sessions, parallel forums and workshops covered topics ranging from health system sustainability to disease prevention, global health governance and the future of public health, research and innovation.
In a sense, this year’s EHFG felt like a (...)
Ageing and Older People
Health Rights and Patients
Health in all policies
public health programme
In light of the recent PIP breast implant scandal, more monitoring of certification bodies is requested under the new proposed Medical Devices Directive to improve patient safety.
Until now, independent certification bodies, approved by Member States, provided authorisation to medical devices coming into the market.
Some MEPs are calling for a centralised EU authorisation of medical devices, however the Commission will not propose this for the Medical Devices Directive (MDD). Eucomed, (...)
‘Saving Lives and Creating Impact: EU Investment in poverty-related and neglected diseases’ is a new study by the Independent Research Group, Policy Cures, that argues that European funding for poverty related and neglected diseases will have a direct benefit on both developing countries and on Europe. The benefits are excellence in science, jobs, and health security. The study was commissioned by Deutsche Stiftung Weltbevoelkerung, a German foundation.
Poverty-related and (...)
On September 25, the EU Civil Society Forum (CSF) sent a letter to the European Trade Commissioner Karel De Gucht. The letter referred to the access to affordable medicines and negotiations for a European Union (EU) Free Trade Agreement with Moldova.
The EU is in the process of negotiating a Deep and Comprehensive Free Trade Agreement (DCFTA) with the eastern European state of the Republic of Moldova. Allegedly, it contains a provision that could endanger the health of people living with (...)